Biotricity

Biotricity Quick Ratio

Delisted

The Quick Ratio (Acid Test) of Biotricity (BTCY) as of Oct 26, 2026 is 0.15. In the previous year, Quick Ratio (Acid Test) was 0.11 — a change of 30.91% (higher).

Quick Ratio

0.15

YoY

30.91%

Last updated:

Quick Ratio (Acid Test) of Biotricity is 2025 0.15 . Quick Ratio (Acid Test) of Biotricity was 2024 0.11 . It decreases by 30.91% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotricity Stock analysis

What does Biotricity do? Biotricity, Inc. generates revenue through its remote biometric monitoring solutions, primarily targeting healthcare providers and patients with chronic conditions. The company offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases and coronary heart diseases, detect arrhythmias via ambulatory monitoring, and provide real-time remote mobile cardiac telemetry diagnostics. Additionally, Biotricity sells biolife, a health and lifestyle solution for individuals that monitors heart-rhythm, ECG, respiration, calories, temperature, and physical activity through a dedicated device. Healthcare institutions and patients seeking chronic condition management and lifestyle improvement are the primary buyers of these products. The firm's revenue streams are derived from the sale of bioflux systems to medical professionals for diagnostic and post-diagnostic use, while biolife targets individual consumers for personal health monitoring. Bioflux is utilized by physicians for real-time ECG data transmission and arrhythmia detection, and biolife is marketed directly to individuals for comprehensive health tracking. Both products are sold through direct sales channels to their respective target segments. Biotricity's business model relies on the dual focus of medical diagnostics and consumer health solutions. The company's products are designed to serve two distinct market segments: healthcare providers using bioflux for clinical diagnostics and patients using biolife for personal health management. The remote monitoring capabilities of both systems facilitate ongoing health data collection and analysis, supporting chronic disease management and lifestyle enhancement. Biotricity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotricity stock

Quick Ratio (Acid Test) of Biotricity is 0.15 in 2025.

Quick Ratio (Acid Test) of Biotricity changed from 0.11 to 0.15, representing a 30.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Biotricity since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Biotricity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biotricity

All Key Metrics — Biotricity